Bluejay Diagnostics, Inc. (BJDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 2, 2026, details a private placement of securities by Bluejay Diagnostics, Inc., an emerging growth company incorporated in Delaware. The transaction closed on June 5, 2026, with H.C. Wainwright & Co. serving as the exclusive placement agent.
Key Financial Metrics and Transaction Details
- Proceeds: The Company received approximately $7.7 million in net proceeds after fees.
- Securities Issued:
- 3,655,917 Pre-Funded Warrants (exercise price: $0.0001).
- 3,655,917 Series G Warrants (exercise price: $2.075; 5-year term).
- 3,655,917 Series H Warrants (exercise price: $2.075; 24-month term).
- Pricing: The combined price per unit (Pre-Funded Warrant + Series G + Series H) was $2.324.
- Placement Agent Compensation:
- Cash fees: 7% cash fee and 1% management fee on gross proceeds.
- Warrants: 255,915 Placement Agent Warrants issued (exercise price: 125% of the combined offering price plus $0.0001).
- Future fees: 7% cash fee and 1% management fee on future cash exercises of Series G and H warrants, plus 7% of shares underlying exercised warrants issued as new warrants.
Material Changes and Agreements
The filing reports the entry into a Material Definitive Agreement (Item 1.01) and Unregistered Sales of Equity Securities (Item 3.02). Key contractual terms include:
- Registration Rights: The Company must file a resale registration statement by June 17, 2026, and use best efforts to declare it effective promptly. Failure to meet deadlines triggers liquidated damages.
- Lock-up Provisions:
- 90-day moratorium on issuing new equity or convertible securities after the Effective Date of the registration statement.
- One-year restriction on "variable rate transactions," stock splits, or recapitalizations without majority investor consent (with exceptions for maintaining Nasdaq listing).
- Beneficial Ownership Limitations: Warrant holders cannot exercise if it results in beneficial ownership exceeding 4.99% or 9.99% (electable), unless 61 days' notice is given to increase the limit.
- Fundamental Transaction Rights: Warrant holders may receive cash equal to the Black Scholes value of unexercised warrants in the event of a fundamental transaction.
Outlook, Risks, and Contingencies
The filing does not provide specific financial guidance, revenue forecasts, or management commentary on future operational performance. The primary risks identified are contingent on the Company's ability to:
- File and declare the resale registration statement effective by the required deadlines to avoid liquidated damages.
- Maintain compliance with the restrictive covenants regarding future equity issuances and capital structure changes.
Investor Verification Checklist
- Verify the filing date and effectiveness status of the resale registration statement (deadline: June 17, 2026).
- Confirm the exact number of shares outstanding post-closing to calculate the 4.99%/9.99% beneficial ownership limits accurately.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific definitions of "variable rate transactions" and exceptions to the lock-up.
- Monitor future filings for the exercise of Series G and H warrants to assess potential dilution and additional cash inflows.